RIOK1

Across TCGA pan-cancer cohorts, RIOK1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RIOK1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RIOK1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RIOK1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where RIOK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.360	0.681	.003	42	view →
LSCC	DFS	Median	All	0.832	0.594	.001	34	view →
LUAD	OS	Median	II,III,IV	0.449	0.893	.023	6	view →
CCRCC	DFS	Quartile	III,IV	0.886	0.416	.015	4	view →
UCEC	OS	Median	All	0.837	0.965	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RIOK1–PDAC (OS)

Open the PDAC breakdown →